A Prospective, Multicenter, Observational Study of Bevacizumab in Combined with Chemotherapy As First-Line or Second-Line Treatment in Chinese Metastatic Colorectal Cancer

Shukui Qin,Yanhong Deng,Feng Bi,Tian Shu Liu,Yunpeng Liu,Suzhan Zhang,Jianming Xu,Shu Yongqian,Nong Xu,Changping Wu,Xin Wang,Haijun Zhong,Jifeng Feng,Yulong He,Jianwei Yang

DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e15012

IF: 45.3

2016-01-01

Journal of Clinical Oncology

Abstract:e15012 Background: Bevacizumab (BV) was approved in February 2010 in China with indication of combined with 5-FU for metastatic colorectal cancer (mCRC). Post-marketing surveillance of patients (Pts) who received BV was required because of limited clinical data, especially safety profile in China. In order to understand practical use of BV and guide clinical practice in China, we have studied safety and efficacy of BV combined with chemotherapy (CT) in 1st- or 2nd-line treatment for Pts with mCRC. Methods: The current study is a prospective observational study conducted in 24 Chinese cancer centers. Pts were treated with BV plus CT for mCRC as 1st- or 2nd-line therapy. The primary objective was to investigate the safety profile of these treatments. Results: 606 Pts (median age 56.6 years (22–81); ECOG PS 0-1: 76.7%) were treated with BV plus CT as 1st- line (n = 453) or 2nd- line (n = 153) therapy.The median cycles on BV treatment were 5 (3.0 – 8.0) cycles. The incidence of any AEs (grade ≥ 3 ) was 16.8%. In which grade ≥ 3 AEs related to BV were reported in 10.9% of Pts. AE of special interest (grade ≥ 3) included hypertension (1.8%), proteinuria (0.8%), GI perforation (0.5%), bleeding (3.3%), arterial TE (0.3%), venous TE (1.0%), fistula formation (0.8%) and wound healing complications (0.2%). The safety profile was similar between 1st- and 2nd-line therapies. The ORR and median PFS were 18.3% (95% CI, 15.3%–21.6%) and 9.1 months (95% CI, 8.1–9.8), respectively. The one-year PFS rate and one-year survival rate were 33.1% and 68.8%, respectively. The ORR in KRAS wild-type and mutant Pts were 15.9% (95% CI, 9.0–25.2) and 9.5% (95% CI, 4.7–16.8), respectively. The median PFS was 9.8 months (95% CI, 6.7–12.3) in KRAS wild-type Pts and 8.6 months (95% CI, 6.2–9.9) in KRAS mutant Pts. Conclusions: The safety profile of BV containing regimen in China seemed comparable with those reported from other pivotal studies or Chinese registration study (ARTIST). BV combined with standard CT is effective as observed in our registry. However, due to the short treatment cycles, the ORR in this observational study is not good as previous studies. Clinical trial information: NCT01319877.